FULCRUM THERAPEUTICS ($FULC) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of -$0.31 per share, beating estimates of -$0.32 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $FULC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FULCRUM THERAPEUTICS Insider Trading Activity
FULCRUM THERAPEUTICS insiders have traded $FULC stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 3 sales selling 4,175,139 shares for an estimated $58,377,021.
- ROBERT J GOULD has made 0 purchases and 2 sales selling 30,000 shares for an estimated $326,352.
- CURTIS GALE OLTMANS (Chief Legal Officer) sold 3,452 shares for an estimated $44,599
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
FULCRUM THERAPEUTICS Hedge Fund Activity
We have seen 99 institutional investors add shares of FULCRUM THERAPEUTICS stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,175,139 shares (-40.8%) from their portfolio in Q4 2025, for an estimated $47,220,822
- BRAIDWELL LP added 2,841,734 shares (+1294.7%) to their portfolio in Q4 2025, for an estimated $32,140,011
- POINT72 ASSET MANAGEMENT, L.P. added 2,398,232 shares (+inf%) to their portfolio in Q4 2025, for an estimated $27,124,003
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,157,000 shares (-47.0%) from their portfolio in Q3 2025, for an estimated $19,844,400
- SIREN, L.L.C. added 1,950,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,054,500
- FIRST TURN MANAGEMENT, LLC added 1,892,683 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,406,244
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,180,111 shares (+21.9%) to their portfolio in Q4 2025, for an estimated $13,347,055
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
FULCRUM THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $FULC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- Piper Sandler issued a "Overweight" rating on 10/30/2025
To track analyst ratings and price targets for FULCRUM THERAPEUTICS, check out Quiver Quantitative's $FULC forecast page.
FULCRUM THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $FULC recently. We have seen 7 analysts offer price targets for $FULC in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- An analyst from JP Morgan set a target price of $20.0 on 01/12/2026
- Gregory Renza from Truist Securities set a target price of $18.0 on 12/11/2025
- Tazeen Ahmad from B of A Securities set a target price of $7.0 on 12/09/2025
- Luca Issi from RBC Capital set a target price of $10.0 on 12/08/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $24.0 on 12/08/2025
- Edward Tenthoff from Piper Sandler set a target price of $23.0 on 12/08/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $25.0 on 12/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
